DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation - Lai, Ssu-Chuan; Su, Yu-Ting; Chi, Ching-Chi; Kuo, Yung-Che; Lee, Kam-Fai; Wu, Yu-Chih; Lan, Pei-Chi; Yang, Muh-Hwa; Chang, Te-Sheng; Huang, Yen-Hua (Journal of experimental & clinical cancer research, 2019)
Keywords: Analysis; Animal experimentation; Animals; Antineoplastic agents; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Cancer; Carcinoma; Carcinoma, Hepatocellular - drug therapy; Carcinoma, Hepatocellular - genetics; Carcinoma, Hepatocellular - metabolism; Cell Line, Tumor; Cytokines; Disease Models, Animal; DNA; DNA (Cytosine-5-)-Methyltransferases - antagonists & inhibitors; DNA (Cytosine-5-)-Methyltransferases - biosynthesis; DNA (Cytosine-5-)-Methyltransferases - genetics; DNA (Cytosine-5-)-Methyltransferases - metabolism; DNA methylation; DNA Methyltransferase 3B; DNMT3b; Drug resistance; Drug Resistance, Neoplasm; Enzyme-linked immunosorbent assay; Female; Health aspects; Hep G2 Cells; Hepatocellular carcinoma; Heterografts; Humans; Inhibitor drugs; Interleukin-6; Interleukin-6 - blood; Interleukin-6 - genetics; Interleukin-6 - metabolism; Interleukins; Kinases; Liver cancer; Liver Neoplasms - drug therapy; Liver Neoplasms - genetics; Liver Neoplasms - metabolism; Medical research; Methyltransferases; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Middle Aged; OCT4; Octamer Transcription Factor-3 - biosynthesis; Octamer Transcription Factor-3 - genetics; Phospho-STAT3; Plasmids; Prognosis; Recurrence (Disease); RNA; RNA interference; Silence; Sorafenib; Sorafenib - pharmacology; STAT3 Transcription Factor - metabolism; Stem cells; Targeted cancer therapy; Transferases; Tumors; Taiwan; United States--US; OCT4; DNMT3b; Phospho-STAT3; Hepatocellular carcinoma; Drug resistance; Interleukin-6